Literature DB >> 27718757

Growth hormone delivery devices: current features and potential for enhanced treatment adherence.

Tilman R Rohrer1, Reiko Horikawa2, Anne-Marie Kappelgaard3.   

Abstract

INTRODUCTION: Adherence to daily growth hormone (GH) injections optimizes treatment benefit; however, adherence rates are sometimes poor. Reasons for poor adherence and persistence are multifaceted. GH injection devices are undergoing continual improvement to enhance adherence. Areas covered: This review evaluates published data on the evolution of GH injection devices to meet patients' needs and preferences, patients' perception of new devices and the projected impact of device developments on adherence. Published studies were identified through literature database searches including EMBASE and PubMed (January 1985-November 2015). Expert opinion: Patient needs and preferences trend towards convenient, easy-to-use devices that enable self-injection, minimize injection preparation steps by reducing the medication reconstitution and storage requirements, and reduce injection pain. In comparative studies, devices that patients considered easier to use than comparator devices were associated with reduced handling errors, fear of injection (needle anxiety/needle phobia) and pain upon needle insertion, and were thus preferred. A combination of the following items are expected to increase patient motivation to better adhere to therapy and improve treatment outcomes: advances in GH injection devices, educating patients regarding injection device and injection technique, and ongoing support from healthcare professionals, including comprehensive education about their condition, medication and expected outcomes.

Entities:  

Keywords:  Accuracy; adherence; device; growth hormone; non-adherence; pen; somatropin; treatment; usability

Mesh:

Substances:

Year:  2016        PMID: 27718757     DOI: 10.1080/17425247.2017.1243526

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  9 in total

1.  Patients' perceptions on the usability of the SurePal™ self-injection device for Omnitrope®: a questionnaire-based observational study conducted in paediatric patients in France.

Authors:  Régis Coutant; Clémentine Dupuis; Patricia Pigeon; Phillipe Rebaud
Journal:  Ther Adv Endocrinol Metab       Date:  2017-10-02       Impact factor: 3.565

Review 2.  Shared Decision-Making in Growth Hormone Therapy-Implications for Patient Care.

Authors:  Carlo L Acerini; David Segal; Sherwin Criseno; Kei Takasawa; Navid Nedjatian; Sebastian Röhrich; Mohamad Maghnie
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-22       Impact factor: 5.555

3.  Improvement of treatment adherence with growth hormone by easypod™ device: experience of an Italian centre.

Authors:  Maria Cristina Maggio; Beatrice Vergara; Paolo Porcelli; Giovanni Corsello
Journal:  Ital J Pediatr       Date:  2018-09-27       Impact factor: 2.638

Review 4.  Achieving Optimal Short- and Long-term Responses to Paediatric Growth Hormone Therapy

Authors:  Jan M. Wit; Asma Deeb; Bassam Bin-Abbas; Angham Al Mutair; Ekaterina Koledova; Martin O. Savage
Journal:  J Clin Res Pediatr Endocrinol       Date:  2019-07-09

Review 5.  Short and Long-Term Effects of Growth Hormone in Children and Adolescents With GH Deficiency.

Authors:  Michael B Ranke
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-01       Impact factor: 5.555

6.  Clinicians' Feedback on Patient/Carer Experience After Switching of Growth Hormone Treatment in Pediatric Patients During COVID-19.

Authors:  Joanne Blair; Kelly Warth; Yashasvi Suvarna; Marco Cappa
Journal:  Patient Prefer Adherence       Date:  2021-09-21       Impact factor: 2.711

7.  A new pen device for injection of recombinant human growth hormone: a convenience, functionality and usability evaluation study.

Authors:  Maritta Sauer; Carole Abbotts
Journal:  Patient Prefer Adherence       Date:  2017-12-27       Impact factor: 2.711

Review 8.  Mesoporous Silica Nanoparticles as Carriers for Therapeutic Biomolecules.

Authors:  Rafael R Castillo; Daniel Lozano; María Vallet-Regí
Journal:  Pharmaceutics       Date:  2020-05-07       Impact factor: 6.321

Review 9.  Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review.

Authors:  Anja St Clair-Jones; Francesca Prignano; Joao Goncalves; Muriel Paul; Philipp Sewerin
Journal:  Rheumatol Ther       Date:  2020-11-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.